- Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
Aug 27, 2025 · businesswire.com
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Blueprint insiders received substantial benefits as part of change of control arrangements and certain insiders may have had conflicts of interests. We are investigating whe.
- SHAREHOLDER ALERT: THE ADEMI FIRM INVESTIGATES THE BLUEPRINT MEDICINES CORPORATION TRANSACTION
Aug 27, 2025
MILWAUKEE--(BUSINESS WIRE)--THE ADEMI FIRM IS INVESTIGATING BLUEPRINT (NASDAQ: BPMC) AND ITS TRANSACTION WITH SANOFI. CLICK HERE TO LEARN HOW TO JOIN OUR INVESTIGATION AND OBTAIN ADDITIONAL INFORMATION OR CONTACT US AT GADEMI@ADEMILAW.COM OR TOLL-FREE: 866-264-3995. THERE IS NO COST OR OBLIGATION TO YOU. IN THE TRANSACTION, BLUEPRINT INSIDERS RECEIVED SUBSTANTIAL BENEFITS AS PART OF CHANGE OF CONTROL ARRANGEMENTS AND CERTAIN INSIDERS MAY HAVE HAD CONFLICTS OF INTERESTS. WE ARE INVESTIGATING WHE.
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
Jul 14, 2025 · globenewswire.com
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Blueprint Medicines Corporation (NASDAQ: BPMC ) related to its sale to Sanofi, S.A. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (“CVR”) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Is it a fair deal?
- $HAREHOLDER ALERT: THE M&A CLASS ACTION FIRM ANNOUNCES AN INVESTIGATION OF BLUEPRINT MEDICINES CORPORATION (NASDAQ: BPMC)
Jul 14, 2025
NEW YORK, JULY 14, 2025 (GLOBE NEWSWIRE) -- CLASS ACTION ATTORNEY JUAN MONTEVERDE WITH MONTEVERDE & ASSOCIATES PC (THE “M&A CLASS ACTION FIRM”), HAS RECOVERED MILLIONS OF DOLLARS FOR SHAREHOLDERS AND IS RECOGNIZED AS A TOP 50 FIRM IN THE 2024 ISS SECURITIES CLASS ACTION SERVICES REPORT. THE FIRM IS HEADQUARTERED AT THE EMPIRE STATE BUILDING IN NEW YORK CITY AND IS INVESTIGATING BLUEPRINT MEDICINES CORPORATION (NASDAQ: BPMC ) RELATED TO ITS SALE TO SANOFI, S.A. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SANOFI WILL PAY $129.00 PER SHARE IN CASH AT CLOSING, AND BLUEPRINT SHAREHOLDERS ALSO WILL RECEIVE ONE NON-TRADEABLE CONTINGENT VALUE RIGHT (“CVR”) ENTITLING THE HOLDER TO RECEIVE TWO POTENTIAL MILESTONE PAYMENTS OF $2.00 AND $4.00 PER CVR FOR THE ACHIEVEMENT, RESPECTIVELY, OF FUTURE DEVELOPMENT AND REGULATORY MILESTONES FOR BLU-808. IS IT A FAIR DEAL?
- BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Jun 20, 2025 · businesswire.com
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive t.
- BLUEPRINT MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF BLUEPRINT MEDICINES CORPORATION - BPMC
Jun 20, 2025
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (“KSF”) ARE INVESTIGATING THE PROPOSED SALE OF BLUEPRINT MEDICINES CORPORATION (NASDAQGS: BPMC) TO SANOFI (NASDAQGS: SNY). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF BLUEPRINT WILL RECEIVE $129.00 PER SHARE IN CASH AT CLOSING, AND ALSO WILL RECEIVE ONE NON-TRADEABLE CONTINGENT VALUE RIGHT (CVR) ENTITLING THE HOLDER TO RECEIVE T.
- HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)
Jun 15, 2025 · globenewswire.com
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Blueprint Medicines Corporation (NASDAQ: BPMC ) related to it sale to Sanofi. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Is it a fair deal?
- HAPPY FATHER'S DAY! AND $HAREHOLDER ALERT: CLASS ACTION ATTORNEY JUAN MONTEVERDE INVESTIGATES THE MERGER OF BLUEPRINT MEDICINES CORPORATION (NASDAQ: BPMC)
Jun 15, 2025
NEW YORK, JUNE 15, 2025 (GLOBE NEWSWIRE) -- CLASS ACTION ATTORNEY JUAN MONTEVERDE WITH MONTEVERDE & ASSOCIATES PC (THE “M&A CLASS ACTION FIRM”), HAS RECOVERED MILLIONS OF DOLLARS FOR SHAREHOLDERS AND IS RECOGNIZED AS A TOP 50 FIRM IN THE 2024 ISS SECURITIES CLASS ACTION SERVICES REPORT. THE FIRM IS HEADQUARTERED AT THE EMPIRE STATE BUILDING IN NEW YORK CITY AND IS INVESTIGATING BLUEPRINT MEDICINES CORPORATION (NASDAQ: BPMC ) RELATED TO IT SALE TO SANOFI. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SANOFI WILL PAY $129.00 PER SHARE IN CASH AT CLOSING, AND BLUEPRINT SHAREHOLDERS ALSO WILL RECEIVE ONE NON-TRADEABLE CONTINGENT VALUE RIGHT (CVR) ENTITLING THE HOLDER TO RECEIVE TWO POTENTIAL MILESTONE PAYMENTS OF $2.00 AND $4.00 PER CVR FOR THE ACHIEVEMENT, RESPECTIVELY, OF FUTURE DEVELOPMENT AND REGULATORY MILESTONES FOR BLU-808. IS IT A FAIR DEAL?
- Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Jun 12, 2025 · prnewswire.com
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass. , June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM).
- BLUEPRINT MEDICINES ANNOUNCES DATA REINFORCING SUSTAINED CLINICAL EFFICACY AND WELL-TOLERATED SAFETY PROFILE OF LONG-TERM AYVAKIT®/AYVAKYT® (AVAPRITINIB) TREATMENT AT 2025 EHA AND EAACI CONGRESSES
Jun 12, 2025
-- BREADTH OF PRESENTATIONS, INCLUDING ONE ORAL AND TWO FLASH TALKS, SHOWCASE BLUEPRINT MEDICINES' LEADERSHIP ROLE IN ADVANCING CARE FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS -- CAMBRIDGE, MASS. , JUNE 12, 2025 /PRNEWSWIRE/ -- BLUEPRINT MEDICINES CORPORATION (NASDAQ: BPMC) TODAY ANNOUNCED DATA PRESENTATIONS REFLECTING OVER A DECADE OF COLLABORATION WITH CLINICAL EXPERTS AND PATIENT ADVOCATES TO TRANSFORM THE TREATMENT OF SYSTEMIC MASTOCYTOSIS (SM).
